ClinicalTrials.gg
TerminatedNCT01021423RENEWUpdated Nov 19, 2019Results posted

A Study to Evaluate the Efficacy of Lenalidomide as Maintenance Therapy After Completion of First-line Combination Chemotherapy in Patients With Mantle Cell Lymphoma (MCL).

A Phase 3 interventional study of Lenalidomide and Placebo in Mantle Cell Lymphoma and Non-Hodgkin's Lymphoma, sponsored by Celgene. Terminated at 92 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-19.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment

Why this study was terminated
Terminated by sponsor due to new unpublished data that rendered the current design of the study no longer clinically relevant. There were no safety concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
9
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing lenalidomide in Lymphoma, Mantle-Cell — 5 open to participants now, 8 under way, none of them phase 3. Lenalidomide · Lymphoma, Mantle-Cell.

Enrollment
37th of 43
9 · median 39
Started
2010
with 5 others
Phase 3
4 of 44
none open now
Registered
12th of 44
by date
Lead sponsor
4 of 44
Celgene

Among the 44 studies testing lenalidomide in Lymphoma, Mantle-Cell, this one is the 37th largest by enrollment of the 43 interventional ones that give a count, is one of 6 that started in 2010, is one of 4 in phase 3, and was the 12th registered.

Lymphoma, Mantle-Cell

1,221 studies on the registry are indexed under Lymphoma, Mantle-Cell; 155 are open to participants now.

Browse Lymphoma, Mantle-Cell studies →

Open to participants now

5 of the 44 studies testing lenalidomide in Lymphoma, Mantle-Cell are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About lenalidomide

Lenalidomide: first FDA approval 2005 (REVLIMID), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 92 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing lenalidomide in Lymphoma, Mantle-Cell, or all of them as a file.
02

Study summary

A study to evaluate the efficacy of lenalidomide as maintenance therapy after completion of first-line combination chemotherapy in patients with mantle cell lymphoma (MCL) who are not candidates for transplantation and have achieved partial response (PR) or complete response (CR).

This study was prematurely terminated by the sponsor in light of new unpublished data that rendered the current design of the study no longer clinically relevant. A study design with the control arm of no active treatment was no longer appropriate. The termination of the trial was not based on any safety concerns in the study.

03

Conditions studied

  • Mantle Cell Lymphoma
  • Non-Hodgkin's Lymphoma

Keywords

  • Mantle Cell Lymphoma
  • Non-Hodgkin's Lymphoma
  • CC-5013
  • Revlimid
  • Lenalidomide
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • -proven mantle cell non-Hodgkin's lymphoma,
  • One of the following induction chemotherapy regimens with rituximab: (1) combination regimen containing all of the following components: cyclophosphamide, vincristine, adriamycin and a ; (2) Fludarabine containing regimen such as FC (fludarabine, cyclophosphamide)
  • Achieved a PR or better response after the first-line induction chemotherapy regimen (assessed by 2007 Revised Response Criteria for Malignant Lymphoma)
  • performance status score of ≤ 2
  • Willing to follow pregnancy precaution

Exclusion criteria

Exclusion Criteria:

  • Patients who have received more than 1 line of induction chemotherapy;
  • Patients who have received less than 4 cycles of R-CHOP, R-CHOP-like, or R-FC are ineligible;
  • Patients who achieved stable disease or progressive disease as best response with -induction chemotherapy;
  • Any of the following laboratory abnormalities:
  • (ANC) \< 1,500 cells/mm3 (1.5*10\^9/L)
  • count \< 60,000/mm\^3 (60*10\^9/L)
  • Serum (AST/SGOT) or alanine transaminase (ALT/SGPT)) > 3.0 times (ULN), except in patients with documented liver involvement by lymphoma
  • Serum > 1.5 times ULN, except in case of Gilbert's Syndrome and documented liver involvement by lymphoma
  • Calculated (i.e. Cockcroft-Gault formula) of \< 30 mL /min
  • Active or any history of central nervous system (CNS) lymphoma or by lymphoma
  • Subjects at high risk for deep vein thrombosis (DVT) not willing to take DVT prophylaxis
  • Known seropositive for or active viral infection with (HIV), virus (HBV) or virus (HCV)
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    Lenalidomide

    Lenalidomide - 15 mg orally once daily on Days 1-21 of every 28-day cycle for a maximum of 2 years or until disease progression, unacceptable toxicity develops or voluntary withdrawal.

    Drug: Lenalidomide

  • Experimental
    Placebo

    Placebo (identical matched capsule) orally once daily on Days 1-21 of every 28-day cycle for a maximum of 2 years or until disease progression, unacceptable toxicity develops or voluntary withdrawal.

    Other: Placebo

Interventions

  • 15 mg orally once daily on Days 1-21 of every 28-day cycle for a maximum of 2 years or until disease progression, unacceptable toxicity develops or voluntary withdrawal.

    Also known as: Revlimid

  • OtherPlacebo

    Placebo (identical matched capsule) orally once daily on Days 1-21 of every 28-day cycle for a maximum of 2 years or until disease progression, unacceptable toxicity develops or voluntary withdrawal.

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS)

    PFS is defined as the time from randomization into the study to the first observation of disease progression or death due to any cause. Progression, as defined by the 2007 Revised Response Criteria for Malignant Lymphoma (Cheson, 2007), is any new lesion or increase by 50% of previously involved sites from nadir. Study terminated prematurely. Analysis not conducted.

    Time frame: up to 7 years

Secondary outcomes

  1. Overall Survival

    Overall survival was defined as the time from randomization to death from any cause. Study terminated prematurely. Analysis not conducted.

    Time frame: up to 7 years

  2. Participants With Treatment Emergent Adverse Events (TEAEs)

    Participants with treatment-emergent adverse events (TEAEs) during the treatment period plus 30 days. A participant with multiple occurrences of an adverse event within a category is counted only once in that category. Adverse events were evaluated by the investigator. The National Cancer Institute (NCI)'s Common Toxicity Criteria for AEs (NCI CTC) was used to grade AE severity. Severity grade 3= severe and undesirable AE. Severity grade 4= life-threatening or disabling AE.

    Time frame: up to 9 months

  3. Time to Progression

    Time to progression was defined as the time from the date of randomization until the first date of documented disease progression. Study terminated prematurely. Analysis not conducted.

    Time frame: up to 7 years

  4. Time to Treatment Failure

    Time to treatment failure was defined as the time from randomization until the date at which a participant was removed from treatment due to progression, toxicity, refusal or death or received another Non-Hodgkin Lymphoma (NHL) therapy, whichever occurs first.

    Time frame: up to 2 years

  5. Participants With a Tumor Response

    Number of participants with a measurable tumor at time of randomization who achieve a response. Complete response (CR) is defined as the complete disappearance of all detectable clinical and radiographic evidence of disease and the disappearance of all disease-related symptoms if present before therapy. Partial response (PR) is defined as the regression of measurable disease and no appearance of new sites of disease. For full definitions, please refer to the 2007 Revised Response Criteria for Malignant Lymphoma (Cheson 2007). Study terminated prematurely. Analysis not conducted.

    Time frame: up to 7 years

07

Results

Posted Dec 2, 2011
Limitations and caveats
Study terminated early. Most analyses were not performed.

Participant flow

Participant flow — Overall Study
MilestoneLenalidomidePlacebo
Started45
Completed00
Not completed45
Withdrew: Study terminated45

Outcome measures

PrimaryProgression-free Survival (PFS)

PFS is defined as the time from randomization into the study to the first observation of disease progression or death due to any cause. Progression, as defined by the 2007 Revised Response Criteria for Malignant Lymphoma (Cheson, 2007), is any new lesion or increase by 50% of previously involved sites from nadir. Study terminated prematurely. Analysis not conducted.

Time frame:
up to 7 years

No measurements were reported for this outcome.

SecondaryOverall Survival

Overall survival was defined as the time from randomization to death from any cause. Study terminated prematurely. Analysis not conducted.

Time frame:
up to 7 years

No measurements were reported for this outcome.

SecondaryParticipants With Treatment Emergent Adverse Events (TEAEs)

Participants with treatment-emergent adverse events (TEAEs) during the treatment period plus 30 days. A participant with multiple occurrences of an adverse event within a category is counted only once in that category. Adverse events were evaluated by the investigator. The National Cancer Institute (NCI)'s Common Toxicity Criteria for AEs (NCI CTC) was used to grade AE severity. Severity grade 3= severe and undesirable AE. Severity grade 4= life-threatening or disabling AE.

Time frame:
up to 9 months
Reported as:
Number · participants
Participants With Treatment Emergent Adverse Events (TEAEs)
participantsLenalidomidePlacebo
At least one TEAE44
At least one TEAE related to study drug32
At least one NCI CTC grade 3-4 TEAE11
At least one NCI CTC grade 3-4 related to drug11
At least one serious TEAE10
At least one serious TEAE related to drug10
TEAE leading to discontinuation of drug10
Related TEAE leading to discontinuation of drug10
TEAE leading to dose reduction or interruption11
Related TEAE - dose reduction or interruption11
SecondaryTime to Progression

Time to progression was defined as the time from the date of randomization until the first date of documented disease progression. Study terminated prematurely. Analysis not conducted.

Time frame:
up to 7 years

No measurements were reported for this outcome.

SecondaryTime to Treatment Failure

Time to treatment failure was defined as the time from randomization until the date at which a participant was removed from treatment due to progression, toxicity, refusal or death or received another Non-Hodgkin Lymphoma (NHL) therapy, whichever occurs first.

Time frame:
up to 2 years

No measurements were reported for this outcome.

SecondaryParticipants With a Tumor Response

Number of participants with a measurable tumor at time of randomization who achieve a response. Complete response (CR) is defined as the complete disappearance of all detectable clinical and radiographic evidence of disease and the disappearance of all disease-related symptoms if present before therapy. Partial response (PR) is defined as the regression of measurable disease and no appearance of new sites of disease. For full definitions, please refer to the 2007 Revised Response Criteria for Malignant Lymphoma (Cheson 2007). Study terminated prematurely. Analysis not conducted.

Time frame:
up to 7 years

No measurements were reported for this outcome.

Adverse events

Collected over Treatment emergent adverse events occurred during the treatment period, plus 30 days. Due to early termination, the longest experience was 245 days.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lenalidomide—1/4 (25%)4/4 (100%)
Placebo—0/5 (0%)4/5 (80%)
Most frequent serious events
Most frequent serious events
EventLenalidomidePlacebo
Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/40/5
Most frequent other events
Showing 10 of 29
Most frequent other events
EventLenalidomidePlacebo
Herpes zosterInfections and infestations1/40/5
Herpes zoster ophthalmicInfections and infestations1/40/5
Viral rashInfections and infestations1/40/5
ThrombocytopeniaBlood and lymphatic system disorders1/41/5
NeutropeniaBlood and lymphatic system disorders1/40/5
ConstipationGastrointestinal disorders1/41/5
Abdominal pain upperGastrointestinal disorders1/40/5
DiarrhoeaGastrointestinal disorders1/40/5
Dry mouthGastrointestinal disorders1/40/5
FlatulenceGastrointestinal disorders1/40/5

Baseline characteristics

Age, Continuous
Age, Continuous(years)LenalidomidePlaceboTotal
Mean77.8 ± 4.6573.0 ± 6.8975.1 ± 6.17
Sex: Female, Male
Sex: Female, Male(Participants)LenalidomidePlaceboTotal
Female123
Male336
Race (NIH/OMB)
Race (NIH/OMB)(Participants)LenalidomidePlaceboTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White459
More than one race000
Unknown or Not Reported000
Eastern Cooperative Oncology Group (ECOG) Performance Status
Eastern Cooperative Oncology Group (ECOG) Performance Status(participants)LenalidomidePlaceboTotal
Status = 0437
Status = 1022
Response of Mantle Cell Lymphoma (MCL) to chemotherapy at enrollment
Response of Mantle Cell Lymphoma (MCL) to chemotherapy at enrollment(participants)LenalidomidePlaceboTotal
Complete response314
Partial response145
08

Study locations

92 sites
  • Sharp Healthcare Oncology Associates of San Diego
    San Diego, California 92123, United States
  • Rocky Mountain Cancer Center
    Denver, Colorado 80218, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Indiana University Melvin and Bren Simon Cancer Center
    Indianapolis, Indiana 46202, United States
  • Providence Cancer Center
    Indianapolis, Indiana 97213, United States
  • Nebraska Hematology-Oncology, PC
    Lincoln, Nebraska 68506, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Arena Oncology Associates
    Lake Success, New York 11042, United States
  • Weill Cornell Medical College/New York Presbyterian Hospital
    New York, New York 10021, United States
  • SUNY Upstate Medical University
    Syracuse, New York 13210, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
  • Avera Cancer Institute
    Sioux Falls, South Dakota 57105, United States
  • University of Virginia Health Systems
    Charlottesville, Virginia 22908, United States
  • Fakultni nemocnice Hradec Králové II. Interni klinika-Oddeleni klinicke hematologie
    Hradec Králové, 500 05, Czechia
  • Fakultni Nemocnice Olomouc, Hemato-Onkologicka Klinika
    Olomouc, 77520, Czechia
  • Clinic of Oncology Faculty Hospital Motol
    Prague 5, Czechia
  • Fakultni Nemocnice Kralovske Vinohrady
    Praha 10, 10034, Czechia
  • Vseobecna Fakultni Nemocnice
    Praha 2, 12808, Czechia
  • CHU Amiens Sud, Centre de Recherche Clinique - Pharmacologie Clinique
    Amiens Cedex, 80054, France
  • CHU Hôpital Hotel Dieu
    Angers, 49000, France
  • CHU ESTAING, Service d'Hématologie
    Clermont Ferrand Cedex 1, 63003, France
  • Hôpital Henri Mondor Unité Hémopathies Lymphoides
    Créteil, 94010, France
  • CHD Les Oudairies, Service d'Oncologie Hématologie
    La Roche sur Yon, 85000, France
  • Centre Hospitalier Lyon Sud, Pavillon Marcel Bérard 1F Hématologie
    La Tronche, 38700, France
  • CHRU - Hôpital Claude Huriez
    Lille Cedex, 59037, France
  • CHU Montpellier - Hôpital Saint Eloi Hématologie et Oncologie Médicale
    Montpellier cedex 5, 34295, France
  • CHRU - Hotel Dieu
    Nantes Cedex 1, 44093, France
  • Hôpital Saint-Louis
    Paris Cedex 10, 75475, France
  • CHRU - Hôpital du Haut Lévêque, maladies du sang, Centre François Magendie
    Pessac, 33604, France
  • Centre Hospitalier Lyon Sud, Pavillon Marcel Bérard 1F Hématologie
    Pierre Bénite Cedex, 69495, France
  • CHU de Poitiers, Pôle Régional de Cancérologie, Service d'Oncologie Hématologie et Thérapie Cellulaire
    Poitiers, 86000, France
  • CHU de Reims, Hôpital Robert Debré, Hématologie Clinique
    Reims Cedex, 51092, France
  • Hôpital Pontchaillou Hématologie Clinique
    Rennes Cedex, 35033, France
  • Centre Henri Becquerel
    Rouen Cedex 1, 76038, France
  • Hôpital Purpan CHU de Toulouse
    Toulouse cedex 9, 31059, France
  • Hôpital Bretonneau - CHU Tours
    Tours, 37044, France
  • CHU de Nancy Hôpital de Brabois, Service d'Hématologie et Médecine Interne
    Vandoeuvre Les Nancy, 54511, France
  • Universitätsklinikum Essen Zentrum für Innere Medizin
    Essen, 45122, Germany
  • Universitätsklinikum Freiburg - Medizinische Klinik - Abteilung Innere Medizin I: Hämatologie und Onkologie
    Freiburg, 79106, Germany
  • UKG Universitätsklinikum Göttingen Zentrum Innere Medizin Hämatologie / Onkologie
    Göttingen, 37099, Germany
  • Asklepios Klinik St. Georg - Abteilung für Hämatologie und Stammzelltransplantation
    Hamburg, 20099, Germany
  • Städtisches Klinikum Karlsruhe - Hämatologie / Onkologie Karlsruhe
    Karlsruhe, 76135, Germany
  • Klinikum der Universität München - Großhadern, Medizinische Klinik III
    München, 81377, Germany
  • Universitaetsklinikum Tuebingen
    Tuebingen, 72076, Germany
  • Soroka Medical Center The Institute of Hematology
    Beer Sheva, 84101, Israel
  • Davidoff Cancer Center The Institute of Hematology
    Petah Tiqwa, 49100, Israel
  • Az. Osp. SS.Antonio e Biagio SC Ematologia
    Alessandria, 15121, Italy
  • Ospedale Regionale di Bolzano - Divisione di Ematologia
    Bolzano, 39100, Italy
  • Hematology Dept, Azienda Ospedaliero Universitaria Careggi
    Florence, 50139, Italy
  • Azienda Ospedaliera Universitaria "San Martino"
    Genova, 16132, Italy
  • Az. Osp. Ospedali Riuniti Papardo - Piemonte - S.C. Ematologia
    Messina, 98158, Italy
  • Fondazione San Raffaele del Monte Tabor I.R.C.C.S.
    Milano, 20132, Italy
  • A,O Ospedale Niguarda Ca Granda Dept Hematology
    Milan, 20162, Italy
  • Istituto Nazionale Tumori Fondazione "G. Pascale" - Oncoematologia
    Napoli, 80131, Italy
  • Università del Piemonte Orientale "Amedeo Avogadro"
    Novara, 28100, Italy
  • Policlinico San Matteo - Dip. Di Ematologia
    Pavia, 27100, Italy
  • Az. Osp. Bianchi Melacrino Morelli, Div. Di Ematologia
    Reggio Calabria, 89100, Italy
  • Università Cattolica del Sacro Cuore Policlinico A. Gemelli
    Roma, 00168, Italy
  • IRCCS Casa Sollievo della Sofferenza Div. Di Oncoematologia
    S.Giovanni Rotondo (FG), 71013, Italy
  • Azienda Sanitaria Ospedaliera San Giovanni Battista (Molinette)
    Torino, 10126, Italy
  • Ospedale Cardinale G. Panico - Ematologia e Immunoematologia
    Tricase, 73039, Italy
  • Clinica Ematologica - DIRM Azienda Ospedaliera Universitaria
    Udine, 33100, Italy
  • Małopolskie Centrum Medyczne
    Krakow, 30-510, Poland
  • Wojewodzki Szpital Specjalistczny im. Mikolaja Kopernika
    Lodz, 93510, Poland
  • Dolnoslaskie Centrum Transplantacji Komórkowych
    Wroclaw, 53439, Poland
  • Serviço de Hematologia
    Coimbra, 300-075, Portugal
  • Instituto Português de Oncologia (IPO) de Lisboa
    Lisboa, 1099-023, Portugal
  • Instituto Português de Oncologia (IPO) do Porto
    Porto, 4200-072, Portugal
  • Centro de Cancer, Hospital Espanol Auxilio de Puerto Rico
    San Juan, 00918, Puerto Rico
  • Sverdlovsk Regional Clinical Hospital - Volgogradskaya
    Ekaterinburg, 620102, Russian Federation
  • Republican Clinical Oncological Dispensary
    Kazan, 420029, Russian Federation
  • Russian Oncological Research Centre
    Moscow, 115478, Russian Federation
  • Perm Regional Clinical Hospital
    Perm, 614600, Russian Federation
  • Russian Scientific-research Institute of Hematology and Transfusiology of Federal Medical-biological agency
    St. Petersburg, 191024, Russian Federation
  • State Educational Institution of High Professional Education
    St. Petersburg, 197022, Russian Federation
  • Federal Center of Heart, Blood and Endocrinology n.a. V.A. Almazov Rosmedtechnologies
    St. Petersburg, 197341, Russian Federation
  • State Healthcare Institution "Volgograd Regional Clinical OncologyDispensary #1
    Volgograd, 400138, Russian Federation
  • Hospital Universitario Vall d´Hebrón Hematology Department
    Barcelona, 08035, Spain
  • Hospital de Madrid Norte- Sanchinarro
    Madrid, Spain
  • Hospital Costa del Sol, Oncology
    Marbella (Málaga), 29600, Spain
  • C. H. de Orense
    Ourense, Spain
  • Clinica Universitaria de Navarra, Hematology
    Pamplona, 31008, Spain
  • Hospital Clínico Universitario de Salamanca
    Salamanca, 37007, Spain
  • Hospital Marques de Valdecilla
    Santander, 39008, Spain
  • Kent and Canterbury Hospital
    Canterbury, Kent, CT1 3NG, United Kingdom
  • Torbay Hospital
    County Of Devon, TQ2 7AA, United Kingdom
  • Royal Devon & Exeter Hospital
    Exeter, EX2 5DW, United Kingdom
  • Beatson West of Scotland Cancer Centre
    Glasgow, G12 OXL, United Kingdom
  • Barts & The London NHS Trust Medical Oncology
    London, EC1M 6BQ, United Kingdom
  • Derriford Hospital
    Plymouth, PL6 8DH, United Kingdom
  • Salisbury NHS Foundation Trust, Haematology
    Salisbury, SP2 8BJ, United Kingdom
  • St Helens Hospital, Lilac Lower Ground
    St. Helens, WA9 3DA, United Kingdom
09

References and documents

Publications

  • Vose JM, Habermann TM, Czuczman MS, Zinzani PL, Reeder CB, Tuscano JM, Lossos IS, Li J, Pietronigro D, Witzig TE. Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation. Br J Haematol. 2013 Sep;162(5):639-47. doi: 10.1111/bjh.12449. Epub 2013 Jul 9. PubMed 23834234 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2010 to primary completion in Mar 2011, 11 months.

Results were first posted in Dec 2011, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2009
First posted
Nov 30, 2009
StartActual
Apr 1, 2010
Primary completionActual
Mar 1, 2011
CompletionActual
Mar 1, 2011
Results first posted
Dec 2, 2011
Last update
Nov 19, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01021423
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Nov 30, 2009
Start date
Apr 1, 2010
Primary completion
Mar 1, 2011
Completion
Mar 1, 2011
Results posted
Dec 2, 2011
Last update
Nov 19, 2019

Study contacts

Martin Dreyling, Prof. Dr
principal investigator · Medizinische Klinik III der Universität München

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenalidomide

Start the discussion